ELI CASDIN

Eli Casdin stands as a leading figure in the life science investment landscape, recognized for his deep expertise and strategic vision. As the Founder and Chief Investment Officer of Casdin Capital, he has built a firm renowned for its focused approach to investing in the rapidly evolving biotech and healthcare technology sectors. Casdin Capital's investment philosophy centers on identifying companies that are pioneering the next generation of tools, platforms, and therapies, often at the convergence of biology and technology.

Under Eli Casdin's leadership, Casdin Capital actively invests across various stages, from early-stage private companies to established public entities. Their core investment focus areas include genomics, proteomics, synthetic biology, advanced diagnostics, drug discovery platforms, and healthcare IT. The firm is particularly adept at spotting companies that provide critical infrastructure and 'picks and shovels' for the broader life science industry, enabling breakthroughs in research and clinical applications. This strategic focus has positioned Casdin Capital as a key enabler of innovation in precision medicine and biotechnology.

Before establishing Casdin Capital in 2011, Eli Casdin honed his extensive financial and scientific acumen through significant roles at other leading institutions. He served as a General Partner at Alliance Bernstein, where he was instrumental in co-founding and managing a highly successful sector-dedicated healthcare fund. Prior to his tenure at Alliance Bernstein, Casdin gained valuable experience as a research analyst at Bear Stearns, further solidifying his analytical capabilities and understanding of market dynamics within the healthcare sector. His career trajectory showcases a consistent dedication to understanding and investing in the complex world of life sciences, underpinned by a strong academic foundation from Columbia University.

Eli Casdin's investment track record includes involvement in numerous groundbreaking companies that have reshaped the life science industry. While specific individual investments are made by Casdin Capital, the firm has been an early supporter and significant investor in companies like 10x Genomics, Guardant Health, Adaptive Biotechnologies, and Recursion Pharmaceuticals. These investments highlight his firm's ability to identify and support companies that are not only financially promising but also poised to make substantial scientific and medical impacts. His strategic insights continue to drive Casdin Capital's success in navigating the dynamic and high-growth life science market.